Wegovy edges closer to PBS listing in Australia for high-risk obesity patients

Semaglutide, marketed as Wegovy, has received a key recommendation from Australia's Pharmaceutical Benefits Advisory Committee (PBAC) for inclusion on the Pharmaceutical Benefits Scheme (PBS), targeting adults with established cardiovascular disease and obesity. This decision, announced late Friday following the PBAC's November meeting, marks a significant step toward subsidized access for a vulnerable group facing high treatment costs.

The recommendation specifies strict eligibility: patients must have experienced a cardiovascular event such as a heart attack, stroke, or symptomatic peripheral arterial disease. Access is limited to those with a BMI of 35 kg/m² or higher, or 32.5 kg/m² or higher for individuals of Asian, Aboriginal, or Torres Strait Islander ethnicity, aiming to prioritize high-risk cases amid the drug's expense.

Background on Wegovy and GLP-1 drugs

Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, mimics a hormone that promotes satiety and aids weight management. Previously approved by the Therapeutic Goods Administration (TGA) for obesity and, in February 2025, for reducing cardiovascular risks in overweight patients with heart disease, it joins siblings like Ozempic (for diabetes) in addressing Australia's obesity epidemic, where over 30% of adults are obese per national health surveys.


PBAC's move responds to Health Minister Mark Butler's March request for advice on equitable GLP-1 access, balancing benefits against budget strains from high demand.

Implications for equitable access

PBAC's broader review identifies priority groups for GLP-1 subsidies in obesity treatment, emphasizing evidence-based cohorts to ensure cost-effectiveness. Past rejections cited inadequate justification or poor value; this targeted listing could set precedents for drugs like tirzepatide, amid calls from RACGP for tackling health inequities in underserved populations.

Final PBS inclusion awaits ministerial approval, with budgetary impacts notable given potential eligibility for millions. Experts like Bond University's Dr. David Henry highlight complexities in scaling subsidies without long-term data on safety and sustained use.

FAQs

What happens next after the PBAC recommendation?
The Health Minister reviews and decides on PBS listing; if approved, subsidized pricing applies from a set date, but supply shortages (as with Ozempic) could delay rollout.

Why the BMI and ethnicity thresholds?
These reflect higher cardiovascular risks in specified groups and optimize cost-effectiveness, ensuring PBS funds high-need patients over broader populations.

Are there long-term concerns with Wegovy?
Limited data on extended use raises questions on sustainability, side effects like gastrointestinal issues, and weight regain post-treatment; PBAC sought advice on optimal duration.